CombiMatrix Corporation Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



CombiMatrix Appoints Preeminent Pediatric Neurologist Dr. James W. Wheless to its Scientific Advisory Board

IRVINE, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that James W. Wheless, M.D., FAAP, FAAN, has joined its Scientific Advisory BoardDr. Wheless is Professor and Chief of Pediatric Neurology at the University of Tennessee Health Science Center, and is Director of the Neurosciences Institute and Director of Comprehensive Epilepsy Program at Le Bonheur Children's Hospital in Memphis, Tenn.

"We are delighted to have Dr. Wheless, a renowned leader in pediatric neurology, become the newest member of our Scientific Advisory Board (SAB)," said Mark McDonough, President and Chief Executive Officer of CombiMatrix.  "Dr. Wheless brings a fresh perspective in neurology to our SAB, which has already made meaningful contributions in supporting the adoption of our tests.  We look forward to tapping into Dr. Wheless' significant expertise as we develop strategies to further improve our market presence, expand our test portfolio and improve family health diagnostic care."   

"Major advances in pediatric neurology over the past decade have come from the adoption of newer technologies such as chromosomal microarray analysis in prenatal and pediatric testing that allows for the detection of smaller chromosomal variants over karyotyping," said Dr. Wheless.  "Better detection of neurologic disorders is part of a comprehensive approach to improving the lives of pediatric patients and I'm delighted to provide my expertise to further support quality care."

Dr. Wheless is a Diplomat of the American Board of Pediatrics and the American Board of Psychiatry and Neurology with special qualifications in child neurology, clinical neurophysiology and epilepsy.  He is a fellow of the American Academy of Pediatrics and the American Academy of Neurology.  He has been a member of the editorial boards of numerous peer-reviewed journals and is a current member at the Journal of Child Neurology and Neurotherapeutics.  He has written three books and more than 50 chapters related to pediatric neurology, and has authored more than 450 articles published in peer-reviewed journals and abstracts presented at scientific conferences.  He has received numerous awards and honors, including "Who's Who in Medicine and Healthcare," "Who's Who in the World" and "Best Doctors in America." Dr. Wheless received his M.D. from the University of Oklahoma, and completed residencies in pediatrics at the University of Oklahoma and in pediatric neurology at Northwestern University at Children's Memorial Hospital in Chicago.

About CombiMatrix Corporation

CombiMatrix Corporation provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization and high resolution karyotyping.  Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "approximates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding projected results of operations, including projected cash flow-positive operating results, management's future business, operational and strategic plans, recruiting efforts and test menu expansion. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: our estimates of total market sizes for the tests that we offer; our ability to grow revenue and improve gross margin; delays in achieving cash flow-positive operating results; the risk that test volumes and reimbursements level off or decline; the risk that payors decide to not cover our tests or to reduce the amounts they are willing to pay for our tests; the risk that we will not be able to grow our business as quickly as we need to; the inability to raise capital; the loss of members of our sales force; our ability to successfully expand the base of our customers, add to the menu of our diagnostic tests, develop and introduce new tests and related reports, expand and improve our current suite of diagnostic services, optimize the reimbursements received for our molecular testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, steadily increase the size of our customer rosters in all of our genetic testing markets;  our ability to attract and retain a qualified sales force in wider geographies; our ability to ramp production from our sales; rapid technological change in our markets; changes in demand for our future services; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

Company Contact:    Investor Contact:
Mark McDonough    LHA
President & CEO, CombiMatrix Corporation     Jody Cain
(949) 753-0624    (310) 691-7100
     jcain@lhai.com

Primary Logo

Source: CombiMatrix Corporation

News Provided by Acquire Media

Close window | Back to top